Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation

Journal of Clinical Microbiology

Volumn 46, Issue 4, 2008, Pages 1558-1560

  De Cueto, M ^a,b   Rodriguez J M ^b   Soriano, M J ^a   Lopez Cerero L ^a,b   Venero, J ^a   Pascual, A ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLINDAMYCIN; COTRIMOXAZOLE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN G; PROTEIN PARC; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; OFLOXACIN;

AGED; ANAMNESIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; GENE MUTATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY; TREATMENT FAILURE; ANTIBIOTIC RESISTANCE; DRUG EFFECT; ENZYMOLOGY; FATALITY; GENETICS; LOBAR PNEUMONIA; MICROBIOLOGY; MUTATION;

STREPTOCOCCUS PNEUMONIAE;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FATAL OUTCOME; HUMANS; MALE; MUTATION; OFLOXACIN; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

EID: 42449142353     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02066-07     Document Type: Article

References (18)

1. Adam, H. J., K. N. Schurek, K. A. Nichol, C. J. Hoban, T. J. Baudry, N. M. Laing, D. J. Hoban, and G. G. Zhanel. 2007. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob. Agents Chemother. 51:198-207.
2. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2003. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47:2606-2614.
3. Carlavilla, A. B., F. López-Medrano, F. Chaves, V. Villena, J. Echave-Sustaeta, and J. M. Aguado. 2005. Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with emphysema. Enferm. Infecc. Microbiol. Clin. 23:270-273.
4. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing. Fifteenth informational supplement. M-100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Croisier, D., M. Etienne, E. Bergoin, P. E. Charles, C. Lequeu, L. Piroth, H. Portier, and P. Chavanet. 2004. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob. Agents Chemother. 48:1699-1707.
6. de la Campa, A. G., L. Balsalobre, C. Ardanuy, A. Fenol, E. Pérez-Trallero, J. Liñares, and the Spanish Pneumococcal Infection Study Network G03/103. 2004. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain. Emerg. Infect. Dis. 10:1751-1759.
7. Doern, G. V., S. S. Richter, A. Miller, N. Miller, C. Rice, K. Heilmann, and S. Bekmann. 2005. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin. Infect. Dis. 41:139-148.
8. Endimiani, A., G. Brigante, A. A. Bettaccini, F. Luzzaro, P. Grossi, and A. Q. Toniolo. 2005. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infect. Dis. 5:106.
9. Ho, P. L., W. S. Tse, K. W. Tsang, T. K. Kwok, T. K. Ng, V. C. Cheng, and R. M. Chan. 2001. Risk factors for acquisition of levofloxacin resistant Streptococcus pneumoniae: a case-control study. Clin. Infect. Dis. 32:701-707.
10. Low, D. E. 2004. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38:S357-S362.
11. Mandell, L. A., R. G. Wunderink, A. Anzueto, J. G. Bartlett, G. D. Campbell, N. C. Dean, S. F. Dowell, T. M. File, D. M. Musher, M. S. Niederman, A. Torres, and C. G. Whitney. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 44:S27-S72.
12. Morrissey, l., and J. George. 1999. Activities of fluoroquinolone against Streptococcus pneumoniae type II topoisomerascs purified as recombinant proteins. Antimicrob. Agents Chemother. 43:2579-2585.
13. Niederman, M. S., L. A. Mandell, A. Anzueto, J. B. Bass, W. A. Broughton, G. D. Campbell, N. Dean, T. File, M. J. Fine, P. A. Gross, F. Martinez, T. J. Marrie, J. F. Plouffe, J. Ramirez, G. A. Sarosi, A. Torres, R. Wilson, and V. L. Yu. 2001. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163:1730-1754.
14. Pérez-Trallero, E., C. Fernández-Mazarrasa, C. García-Rey, E. Bouza, L. Aguilar, J. García-de-Lomas, F. Baquero, and the Spanish Surveillance Group for Respiratory Pathogens. 2001. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob. Agents Chemother. 45:3334-3340.
15. Pérez-Trallero, E., J. A. Marimón, L. Iglesias, and J. Larruskain. 2003. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg. Infect. Dis. 9:1159-1162.
16. Robicsek, A., G. A. Jacoby, and D. C. Hooper. 2006. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6:629-640.
17. Smith, H. J., M. Walters, T. Hisanaga, G. G. Zhanel, and D. J. Hoban. 2004. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or parC or gyrA mutation-containing Streptococcus pneumoniae isolates. Antimicrob. Agents Chemother. 48:3954-3958.
18. Varon, E., S. Houssage, S. Grondin, L. Gutmann, and the Groupe des Observatoires de la Resistance du Pneumocoque. 2006. Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:572-579.